Hrt Financial LP Hutchmed (China) LTD Transaction History

Hrt Financial LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$13.02 - $19.87 $3.03 Million - $4.63 Million	-233,021 Reduced 77.19%	68,860 $896,000
Q4 2022 Feb 10, 2023	BUY	$7.65 - $15.51 $2.31 Million - $4.68 Million	301,881 New	301,881 $4.46 Million
Q3 2021 Nov 15, 2021	SELL	$35.66 - $42.94 $2.44 Million - $2.94 Million	-68,536 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$23.7 - $39.27 $1.62 Million - $2.69 Million	68,536 New	68,536 $2.69 Million
Q3 2019 Nov 14, 2019	SELL	$17.84 - $22.69 $166,679 - $211,992	-9,343 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$22.0 - $31.78 $205,546 - $296,920	9,343 New	9,343 $205,000

6.88M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.47B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.